Marleen Kok

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi, Lorenzo F. Fanchi, Krijn K. Dijkstra et al. · Nature Medicine · 2020 · 1.4K citations · Full text

Medicine, Oncology, Pathology +14

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Daniel J. McGrail, P.G. Pilié, N.U. Rashid et al. · Annals of Oncology · 2021 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings et al. · Nature Medicine · 2019 · 889 citations · Full text

Medicine, Immunology, Oncology +17

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

Myriam Chalabi, Andrés F. Cardona, Deepti R. Nagarkar et al. · Annals of Oncology · 2020 · 295 citations · Full text

Medicine, Oncology, Pharmacology +15

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer

Dora Hammerl, John W.M. Martens, Mieke Timmermans et al. · Nature Communications · 2021 · 251 citations · Full text

Medicine, Immunology, Oncology +17